Covered recipient · General Payments record
JAMES TURNER
Allopathic & Osteopathic Physicians Internal Medicine Endocrinology, Diabetes & Metabolism
General Payments · PY2022–2025
$318.00
- Reported across 16 records
- CMS publication 2026-06-30
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2025 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $298.43 | 15 |
By paying entity
PY2025 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Corcept Therapeutics | $111.98 | 5 |
| Novo Nordisk AS | $42.04 | 2 |
| Xeris Pharmaceuticals, Inc. | $28.76 | 1 |
| Amgen Inc. | $28.06 | 2 |
| Lilly USA, LLC | $20.71 | 1 |
| Neurocrine BioSciences, Inc. | $18.59 | 1 |
| Soleno Therapeutics, Inc. | $18.56 | 1 |
| Acella Pharmaceuticals, LLC | $16.86 | 1 |
| CeQur Corporation | $12.87 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2025 (15)
Ordering applied by this site (paying entity, then date) · record values are shown as CMS published them
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Acella Pharmaceuticals, LLC | $16.86 | 12/03/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1241765777 | CMS |
| Amgen Inc. | $13.66 | 11/18/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1227190162 | CMS |
| Amgen Inc. | $14.40 | 12/17/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1227190164 | CMS |
| CeQur Corporation | $12.87 | 11/10/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1228227140 | CMS |
| Corcept Therapeutics | $15.29 | 10/24/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1214187576 | CMS |
| Corcept Therapeutics | $21.32 | 11/21/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1214187602 | CMS |
| Corcept Therapeutics | $26.33 | 12/05/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1214187612 | CMS |
| Corcept Therapeutics | $26.27 | 12/19/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1214187624 | CMS |
| Corcept Therapeutics | $22.77 | 12/23/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1214187626 | CMS |
| Lilly USA, LLC | $20.71 | 11/25/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1186658491 | CMS |
| Neurocrine BioSciences, Inc. | $18.59 | 12/09/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1243031626 | CMS |
| Novo Nordisk Inc | $19.16 | 10/27/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1188287889 | CMS |
| Novo Nordisk Inc | $22.88 | 11/12/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1188816272 | CMS |
| Soleno Therapeutics, Inc. | $18.56 | 11/25/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1241824828 | CMS |
| Xeris Pharmaceuticals, Inc. | $28.76 | 11/07/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1250160192 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2022, 2025
- Source files
- Dataset page · Bulk file · PY2022 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.